In light of the strong desire to shorten timelines and lower cost for biologics such as monoclonals specially biosimilars, and address surging demand for complex proteins such as bispecific antibodies ...

SHANGHAI, Nov. 22, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced today that it has ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- C3 AI (NYSE: AI), the Enterprise AI application software company, today announced that Genentech, the medical biotechnology company, has selected C3 AI ...

Intravacc offers state-of-the-art analytical methods for identity, content, purity, structure, formulation, stability, and preclinical ...

Good Manufacturing Practice (GMP) compliance in biologics contract manufacturing underpins product safety, efficacy, and regulatory approval. Service providers must integrate robust quality systems, ...

The demands of developing new biologic modalities like bispecific antibodies are pushing the limits of traditional drug manufacturing. For the modern biomanufacturer, process intensification is ...

Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, and ...

As industry shifts to continuous biomanufacturing, engineers integrate process design, digital tools, automation, and ...

As global uncertainty grows, biotech and biopharma companies are rethinking manufacturing strategies to reduce risk and ensure continuity. Onshoring drug substance development for biologics offers a ...

DUBLIN--(BUSINESS WIRE)--The "Biologics Contract Manufacturing Market Industry Trends and Global Forecasts to 2035, by Type of Service Offered, Type of Biologic Manufactured, Type of Expression System ...

Drug Substance manufacturing is a critical component of pharmaceutical production, requiring precise processes, rigorous quality control, and innovative solutions to overcome various challenges. From ...

OKLAHOMA CITY--(BUSINESS WIRE)--Cytovance Biologics today announced a growth equity investment of $22.5 million from Great Point Partners, LLC, a Greenwich, Connecticut private investment firm focused ...